Edition:
India

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

51.70USD
2:29am IST
Change (% chg)

$1.48 (+2.95%)
Prev Close
$50.22
Open
$50.22
Day's High
$51.75
Day's Low
$49.61
Volume
271,053
Avg. Vol
403,979
52-wk High
$65.51
52-wk Low
$37.27

Chart for

About

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment,... (more)

Overall

Beta: 2.89
Market Cap(Mil.): $6,907.90
Shares Outstanding(Mil.): 124.35
Dividend: --
Yield (%): --

Financials

BRIEF-Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders

* IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

21 Dec 2017

BRIEF-Ionis' License Agreement For Huntington's Disease Drug Receives Hart-Scott-Rodino Clearance

* IONIS' LICENSE AGREEMENT FOR HUNTINGTON'S DISEASE DRUG, IONIS-HTT RX, RECEIVES HART-SCOTT-RODINO CLEARANCE

18 Dec 2017

UPDATE 1-'Ground-breaking' new drug gives hope in Huntington's disease

LONDON, Dec 11 Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

11 Dec 2017

BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)

* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE

11 Dec 2017

BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen

* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen

16 Nov 2017

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

15 Nov 2017

BRIEF-Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

* Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

09 Nov 2017

BRIEF-Ionis Pharmaceuticals reports Q3 earnings per share $0.00

* Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017

07 Nov 2017

BRIEF-Ionis submits NDA for Inotersen to the U.S. FDA

* Ionis announces submission of new drug application (NDA) for Inotersen to the U.S. fda Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Ionis submits marketing authorization application for Inotersen to the EMA

* Ionis announces submission of marketing authorization application for inotersen to the European Medicines Agency Source text for Eikon: Further company coverage:

03 Nov 2017

Competitors

Earnings vs. Estimates